Detailed Mechanism Funding and Narrative

Years of mechanism: 2008 2009

Details for Mechanism ID: 8267
Country/Region: Rwanda
Year: 2008
Main Partner: World Health Organization
Main Partner Program: NA
Organizational Type: Multi-lateral Agency
Funding Agency: HHS/CDC
Total Funding: $280,000

Funding for Care: TB/HIV (HVTB): $280,000

In FY 2008, with funding through CDC-WHO central mechanism, WHO in Rwanda will continue supporting

the national TB/HIV program in training, monitoring, supervision, and add on MDR and X-DR TB

surveillance. Specifically, WHO will recruit another national project officer (NPO) to: oversee MDR and X-

DR related activities, work with facilities to find all TB patients who failed first line and second line therapies,

and ensure that MDR cases adhere to their treatment regimens. The NPO will work with the National

Reference Laboratory for identification and diagnosis of second-line drug resistance among MDR patients

who fail treatment or die during treatment. WHO will continue to train hospital staff including administrative

directors on TB infection control and support them to draft and implement plans based on available funds

from EP implementing partners and global fund support at the site level. WHO will expand physician training

on TB diagnostics including chest radiography and atypical presentation of pulmonary disease in PLHI. As

a result, 100 more MDs will be trained. In addition, WHO with EP support will train 30 MDs and hospital

directors from GFATM zones in addition to those from EP zones. WHO will continue to facilitate monthly

supervision of TB/HIV activities in districts by leading the team of supervisors located at PNILT, TRAC, FHI,

AIDSRelief and CDC. This supervision will consist of reviewing data and providing sites with feedback on

achievements and needed changes. Under the leadership of WHO, the team will organize periodic cross-

learning visits with implementing partners and site staff to sites where best practices are exhibited for

TB/HIV collaboration activities. In addition, WHO will facilitate a national discussion on the use of Isoniazid

in preventing TB among PLHIV (including children) based on current available data. In collaboration with

CDC direct TB/HIV program activities, two meetings will be organized for district hospital to present their

infection control plans. The plans will be reviewed by experts and lessons learned in implementing infection

control at district hospital will be shared. In order to better control nosocomial infections based on lessons

learned from TB infection control, WHO will draft a general infection control plan to be implemented at Kigali

national teaching hospital. Experiences from that facility will serve to draft national guidelines on infection

control in Rwanda. This activity complements support from UTAP for TB/HIV integration in Rwanda and will

reduce mortality among PLHIV.

The technical assistance provided by CDC in collaboration with WHO/OGAC and Columbia UTAP will

enhance the quality of national TB/HIV program